Some biochemical and behavioural correlates of a possible animal model of human hyperkinetic syndromes.
D000661:Amphetamine / Q000627:therapeutic use; D000818:Animals; D001285:Atropine / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D002395:Catecholamines / Q000378:metabolism; D002415:Cats; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism*; D002746:Chlorpromazine / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D002855:Chromatography, Thin Layer; D004295:Dihydroxyphenylalanine / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D004558:Electric Stimulation; D005730:Ganglionic Blockers / Q000627:therapeutic use; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D010648:Phenylacetates / Q000378:metabolism; D010852:Picrotoxin / Q000627:therapeutic use; D051381:Rats; D014149:Tranquilizing Agents / Q000627:therapeutic use; D014316:Tritium; D014403:Tubocurarine; D014443:Tyrosine / Q000378:metabolism
D000661:Amphetamine; D001285:Atropine; D002395:Catecholamines; D002746:Chlorpromazine; D002800:Cholinesterase Inhibitors; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D005730:Ganglionic Blockers; D010648:Phenylacetates; D010852:Picrotoxin; D014149:Tranquilizing Agents; D014316:Tritium; D014403:Tubocurarine; D014443:Tyrosine